Commercializing ground breaking discoveries in inflammation and infection

BioAegis Therapeutics’ products will restore depleted levels of plasma gelsolin, an integral and ubiquitous, natural human protein, whose important clinical role is now emerging.


Extensive animal and human studies support the theory that the body’s natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and may cause catastrophic consequences like multiple organ failure, shock and death.


Systemic inflammation causes morbidity and mortality in a myriad of disease states including orphan indications, as well as major acute and chronic diseases such as trauma, burns, renal disease and sepsis.  


Replacement of deficient levels of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs.


BioAegis Therapeutics is currently developing a portfolio of high value, biomarker-directed treatments across a range of indications. 


The company’s team of experienced pharmaceutical executives, scientists and advisors are prepared to rapidly and effectively drive this exciting, novel technology through the next phases of clinical studies and commercialization. 



For more information, contact us at: info@bioaegistherapeutics.com or 1-203-952-6373.

Click here for press release:  BioAegis Therapeutics May 18 2011.pdf